Lanreotide Activity and Synergy in Combination with Targeted Agents in Gastrointestinal Neuroendocrine Tumors (GI-NET): Ex Vivo Analysis of Programmed Cell Death (EVA/PCD) in GI-NETs Isolated from Patients with Advanced Disease Abstract #741

Introduction: Somatostatin receptor ligation can affect vascular signals, induce apoptosis and provide objective responses in some GI-NET patients.
Aim(s): We applied EVA/PCD (Nagourney. Curr Treat Rep Oncol 2006) to examine effects of the somatostatin analogue Lanreotide (Lan) on tumor specimens isolated from 35 GI-NET patients.
Materials and methods: Microspheroids were isolated from surgical specimens and exposed to Lan alone and in combination with Everolimus (Ever), Pazaponib (Paz), Sunitinib (Sun), LX1032 and Bevacizumab (Bev). Drug-induced cell death was measured by delayed loss-of-membrane-integrity and ATP-content. Lethal concentrations (LC50s) were interpolated from dose response curves. Synergy was analyzed by median effect.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Nick Brown

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1404 The Proteasome Inhibitor Bortezomib Is a Highly Effective Treatment Option for Gastroenteropancreatic Neuroendocrine Neoplasms and Sensitizes to DNA Damaging Therapy In Vitro
Introduction: Gastroenteropancreatic neuroendocrine neoplasms are fairly rare tumors with very heterogeneous behavior and molecular characteristics. Their generally slow proliferation render them virtually resistant to many DNA damaging therapeutic approaches. Bortezomib has been shown to be effective in GEP-NENs in vitro but has been withdrawn from clinical assessment due to a small phase II study on bortezomib monotherapy in 2004.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Franziska Briest
#280 Sorafenib and Bevacizumab Combination Targeted Therapy in Advanced Neuroendocrine Tumor: A Phase II Study of the Spanish Neuroendocrine Tumor Group (GETNE0801)
Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Mrs. Cristina Garrido
#597 Primary Hepatic Neuroendocrine Carcinomas Treated with a Combination of Cisplatin and Etoposide as First-Line Chemotherapy: Two Case Reports
Introduction: Because primary hepatic neuroendocrine carcinoma (PHNEC) is extremely rare, a standard regimen has not yet been established. However, the combination of etoposide and cisplatin (EP) has been widely used to treat PHNEC.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Shoichi Nakazuru
#846 Effects of Sunitinib in Combination with Octreotide LAR for Patients with Advanced Pancreatic Neuroendocrine Tumor which Failed Sunitinib or Octreotide LAR Alone
Introduction:
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Others
Presenting Author: Chunmei Bai
Authors: Ying H, Cheng Y, Sun Z, Xue H, ...
#1166 mTOR Pathway Inhibition Sensitizes Insulinoma Cells to Streptozotocin Induced Apoptosis
Introduction: Pancreatic neuroendocrine tumors (pNETs) are generally chemoresistants probably due to low proliferation rate and defects in apoptotic pathway. Targeted therapies are new encouraging options for pNETs however; clinical trials show limited objective response. Combination of chemotherapy and targeted therapy could be a new solution in therapeutic care. Streptozotocin (STZ) is the 1st line of therapy for unresectable pNETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Cécile Vercherat